Rick Epstein, formerly president and CEO of Sonoma Orthopedic Products, is the new CEO of Raynham, Massachusetts-OMNIlife science, Inc.
Rick Epstein New CEO of OMNIlife science
2 min read Premium comments
Secondary#guymayer#omnilifescience#rickepstein
Prior to Sonoma, Rick held several executive leadership positions in prominent organizations including Baxter International and Cardinal Health.
“We are pleased that Rick is joining the OMNI team as our CEO and member of our Board of Directors,” commented Guy Mayer, Executive Chairman of OMNI. “Rick’s experience successfully leading medical device companies through new product introductions will bring great value as we begin launching our new OMNIBotics Active Spacer™ technology for robotically balancing the ligaments in a total knee replacement surgery.”
“I’m looking forward to leading OMNI through an exciting growth stage as surgeons, hospitals and surgery centers begin to experience the benefits OMNI’s products and services will bring to them,” Epstein stated. “The recent FDA clearance of OMNI’s Active Spacer along with the OMNIBotics surgical robot and OMNI’s knee implants provide surgeons with the most advanced tools available for balancing soft tissue, implanting total knees and ultimately providing the best possible outcomes for their total knee patients.”
Epstein told OTW, “Several significant trends which contribute to providing top tier patient outcomes are emerging in total knee replacement surgery.”
“These include surgeon awareness of the benefits of the increased precision of robotic assistance, increased recognition of the advantages of soft tissue balancing, and the move toward an outpatient setting for TKA (total knee arthroplasty) procedures.”
“With robotic-assisted technology that has always been ahead of the market, OMNI is uniquely positioned to address these emerging market needs and provide exceptional value to surgeons, patients, healthcare facilities, and agent distributors.”
“While the leading orthopedic companies recognize the benefits robotic assistance can provide, OMNIBotics with Active Spacer is currently the only system enabling the surgeon to balance the ligaments through dynamic real-time feedback across the entire range of motion and take it into consideration while delivering the precision of robotic-assisted bone cutting. In addition, OMNIBotics with Active Spacer is portable, compact and more cost-effective than alternative systems, ideal for the outpatient environment.”
“OMNI has been the best-kept secret in hip and knee replacement since its founding. Over the next 12 months, our goal is to support many more surgeons, institutions, and distributors, while continuing to advance our technology platform to further improve outcomes. We are developing our strategy and tactics to achieve this goal and determining the right steps to take to ensure that we execute flawlessly. I think that OMNI has an amazing future and I’m excited to have the opportunity to lead the company forward.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.